In this study, the main adverse reactions of HAIC combined with lenvatinib and PD-1 antibody were transaminase elevation, thrombocytopenia, albumin reduction, nausea and vomiting, leukopenia, abdominal pain, and hypertension. Here, RPL17 is linked to Thrombocytopenia.